[{"orgOrder":0,"company":"Inotrem","sponsor":"Roche Diagnostics GmbH","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Peptide","year":"2020","type":"Licensing Agreement","leadProduct":"Nangibotide","moa":"TREM-1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inotrem \/ Roche Diagnostics GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ Roche Diagnostics GmbH"},{"orgOrder":0,"company":"Inotrem","sponsor":"Crohn\u2019s & Colitis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody","year":"2023","type":"Funding","leadProduct":"INO-02","moa":"TREM-1","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inotrem \/ Crohn\u2019s & Colitis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Inotrem \/ Crohn\u2019s & Colitis Foundation"},{"orgOrder":0,"company":"Inotrem","sponsor":"Crohn\u2019s & Colitis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody","year":"2023","type":"Funding","leadProduct":"INO-02","moa":"TREM-1","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inotrem \/ Crohn\u2019s & Colitis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Inotrem \/ Crohn\u2019s & Colitis Foundation"},{"orgOrder":0,"company":"Inotrem","sponsor":"Crohn\u2019s & Colitis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"TREM-1","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inotrem \/ Crohn\u2019s & Colitis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Inotrem \/ Crohn\u2019s & Colitis Foundation"},{"orgOrder":0,"company":"Inotrem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Nangibotide","moa":"TREM-1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inotrem \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ Inapplicable"},{"orgOrder":0,"company":"Inotrem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Nangibotide","moa":"TREM-1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inotrem \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ Inapplicable"},{"orgOrder":0,"company":"Inotrem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Nangibotide","moa":"TREM-1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inotrem \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ Inapplicable"},{"orgOrder":0,"company":"Inotrem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Nangibotide","moa":"TREM-1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inotrem \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ Inapplicable"},{"orgOrder":0,"company":"Inotrem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Nangibotide","moa":"TREM-1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inotrem \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ Inapplicable"},{"orgOrder":0,"company":"Inotrem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Nangibotide","moa":"TREM-1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inotrem \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Inotrem

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : LR12 (nangibotide) targets the immunoreceptor TREM-1 (triggering receptor expressed on myeloid cells-1). It is under phase 2 clinical development for the treatment of Septic Shock.

                          Product Name : LR12

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          August 01, 2024

                          Lead Product(s) : Nangibotide

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : The funding will support the development of INO-02 a new long-acting therapeutic approach to modulate the TREM-1 pathway. TREM-1 is a potential contributor to IBD pathophysiology and targeting this pathway may offer a new treatment for IBD patients with ...

                          Product Name : INO-02

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          September 01, 2023

                          Lead Product(s) : INO-02

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Preclinical

                          Sponsor : Crohn’s & Colitis Foundation

                          Deal Size : Undisclosed

                          Deal Type : Funding

                          blank

                          03

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : The funding will be used to advance Inotrem's inflammatory bowel disease pipeline, including INO-02, a new long-acting therapeutic approach to modulate the TREM-1 pathway.

                          Product Name : INO-02

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          June 11, 2023

                          Lead Product(s) : INO-02

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Preclinical

                          Sponsor : Crohn’s & Colitis Foundation

                          Deal Size : Undisclosed

                          Deal Type : Funding

                          blank

                          04

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Nangibotide is a TREM-1 inhibitor peptide with the potential to restore appropriate inflammatory response, vascular function, and improve post septic shock survival.

                          Product Name : LR12

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          October 25, 2022

                          Lead Product(s) : Nangibotide

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Nangibotide is a TREM-1 inhibitor peptide with the potential to restore appropriate inflammatory response and improve post septic shock survival. ASTONISH demonstrates that TREM-1 modulation with nangibotide improves respiratory, cardiovascular and renal...

                          Product Name : LR12

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          October 13, 2022

                          Lead Product(s) : Nangibotide

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : The objective of the R&D collaboration is to confirm the relationship between the activation of the TREM-1 pathway and the severity and progression of IBD in patients, with the ultimate intention of developing a new treatment.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          April 14, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Preclinical

                          Sponsor : Crohn’s & Colitis Foundation

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          07

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : The ASTONISH Phase IIB study aims at demonstrating safety and clinical efficacy of nangibotide in septic shock patients. It is a global, multicentric study conducted in 48 centers.

                          Product Name : LR12

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          October 06, 2021

                          Lead Product(s) : Nangibotide

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Inotrem’s Phase IIa clinical trial which takes place in France, Belgium and the United States will determine the safety, tolerability and potential signals of efficacy of nangibotide, the company’s lead product, in critically ill COVID-19 patients.

                          Product Name : LR12

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          December 24, 2020

                          Lead Product(s) : Nangibotide

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Nangibotide is a TREM-1 pathway inhibitor with multiple potential indications, such as septic shock and myocardial infarction. TREM-1 is an immunomodulatory receptor found on innate immune cells, which increases and maintains inflammation.

                          Product Name : LR12

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          July 23, 2020

                          Lead Product(s) : Nangibotide

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Inotrem entered a worldwide licensing agreement with Roche Diagnostics for the commercialization of a mechanism-based companion diagnostic test using a soluble plasma protein.

                          Product Name : LR12

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          January 21, 2020

                          Lead Product(s) : Nangibotide

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase II

                          Sponsor : Roche Diagnostics GmbH

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank